The effects of ROS in prostatic stromal cells under hypoxic environment

Figures & data

Figure 1. The expression of ROS in different treatments. 5a = treated with 5a-reductase inhibitors, No 5a = not treated with 5a-reductase inhibitors, 3% O2 + E = 3% O2 + Edaravone (80μM).*p < 0.05, #p > 0.05, by the paired-samples T test.

Table 1. The expression of genes in different specimens.

Groups	HIF-1α	AR	VEGF	IL-8	ROS
BPH specimens	2.926 ± 0.379	2.918 ± 0.264	3.035 ± 0.366	1.970 ± 1.010	82.727 ± 15.923
Controls	0.612 ± 0.568	1.236 ± 0.363	1.094 ± 0.311	1.201 ± 0.115	40.947 ± 10.079
Cell in 21% O2	0.121 ± 0.068	1.027 ± 0.158	0.976 ± 0.128	1.001 ± 0.118	31.680 ± 11.079
χ^2	62.651	61.653	52.281	15.627	59.480
p	<0.01	<0.01	<0.01	<0.01	<0.01

Kruskal–Wallis H Test.

Figure 2. The changes of genes in different treatments: *p < 0.05, #p > 0.05, by the paired-samples T test.

Table 2. The proliferation index in different treatments.

Groups	21% O2	3% O2	3% O2 + edaravone	3% O2	siRNA-HIF-1α	3% O2	1% O2	3% O2
G2 + S(%)	15.193 ± 1.446	21.267 ± 2.866	18.362 ± 1.681	21.267 ± 2.866	19.022 ± 1.405	21.267 ± 2.866	3.481 ± 0.789	21.267 ± 2.866
t	7.809		3.523		2.767		24.695
p	<0.01		<0.01		<0.05		<0.01

The proliferation index was not significant between the 3% O₂+ Edaravone and siRNA-HIF-1α, by the paired-samples t test.

Table 3. The apoptosis in different treatments.

Groups	3% O2	1% O2	3% O2	3% O2 + edaravone	siRNA-HIF-1α	3% O2
apoptosis(%)	2.685 ± 0.351	27.919 ± 4.249	2.685 ± 0.351	12.657 ± 1.400	11.819 ± 0.763	2.685 ± 0.351
t	−23.458		24.783		53.127
p	<0.01		<0.01		<0.01

The apoptosis was not significant between the 3% O₂ + Edaravone and siRNA-HIF-1α, by the paired-samples t test.

Table 4. The expression of genes in different treatments.

Groups	HIF-1α	AR	VEGF	IL-8	ROS
3% O2	2.828 ± 0.318	2.335 ± 0.443	2.688 ± 0.402	1.390 ± 0.545	84.094 ± 10.994
siRNA-HIF-1α	0.826 ± 0.285	2.167 ± 0.398	2.537 ± 0.377	1.271 ± 0.433	82.120 ± 12.168
t	30.452	2.001	2.499	1.860	2.040
p	<0.01	>0.05	<0.05	>0.05	>0.05

By the paired-samples t test.